217 related articles for article (PubMed ID: 33683595)
1. A pathogenic variant in CHEK2 shows a founder effect in Portuguese Roma patients with thyroid cancer.
Pires C; Marques IJ; Dias D; Saramago A; Leite V; Cavaco BM
Endocrine; 2021 Sep; 73(3):588-597. PubMed ID: 33683595
[TBL] [Abstract][Full Text] [Related]
2. A Germline
Zhao Y; Yu T; Chen L; Xie D; Wang F; Fu L; Cheng C; Li Y; Zhu X; Miao G
Thyroid; 2020 Jun; 30(6):924-930. PubMed ID: 32041497
[TBL] [Abstract][Full Text] [Related]
3. CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function.
Pires C; Marques IJ; Valério M; Saramago A; Santo PE; Santos S; Silva M; Moura MM; Matos J; Pereira T; Cabrera R; Lousa D; Leite V; Bandeiras TM; Vicente JB; Cavaco BM
J Biol Chem; 2024 Mar; 300(3):105767. PubMed ID: 38367672
[TBL] [Abstract][Full Text] [Related]
4. A Greek family with a follicular variant of familial papillary thyroid carcinoma: TCO, MNG1, fPTC/PRN, and NMTC1 excluded as susceptibility loci.
Tsilchorozidou T; Vafiadou E; Yovos JG; Romeo G; McKay J; Lesueur F; Bonora E
Thyroid; 2005 Dec; 15(12):1349-54. PubMed ID: 16405407
[TBL] [Abstract][Full Text] [Related]
5.
Brock P; Liynarachchi S; Nieminen TT; Chan C; Kohlmann W; Stout LA; Yao S; La Greca A; Jensen KE; Kolesar JM; Salhia B; Gulhati P; Hicks JK; Ringel MD
Thyroid; 2024 Apr; 34(4):477-483. PubMed ID: 38279823
[No Abstract] [Full Text] [Related]
6. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).
Pereira JS; da Silva JG; Tomaz RA; Pinto AE; Bugalho MJ; Leite V; Cavaco BM
Endocrine; 2015 May; 49(1):204-14. PubMed ID: 25381600
[TBL] [Abstract][Full Text] [Related]
7. CHEK2 mutations and the risk of papillary thyroid cancer.
Siołek M; Cybulski C; Gąsior-Perczak D; Kowalik A; Kozak-Klonowska B; Kowalska A; Chłopek M; Kluźniak W; Wokołorczyk D; Pałyga I; Walczyk A; Lizis-Kolus K; Sun P; Lubiński J; Narod SA; Góźdż S
Int J Cancer; 2015 Aug; 137(3):548-52. PubMed ID: 25583358
[TBL] [Abstract][Full Text] [Related]
8. Whole Genome Sequencing Prioritizes
Srivastava A; Giangiobbe S; Skopelitou D; Miao B; Paramasivam N; Diquigiovanni C; Bonora E; Hemminki K; Försti A; Bandapalli OR
Front Endocrinol (Lausanne); 2021; 12():600682. PubMed ID: 33692755
[TBL] [Abstract][Full Text] [Related]
9. Variants in the ATM-CHEK2-BRCA1 axis determine genetic predisposition and clinical presentation of papillary thyroid carcinoma.
Wójcicka A; Czetwertyńska M; Świerniak M; Długosińska J; Maciąg M; Czajka A; Dymecka K; Kubiak A; Kot A; Płoski R; de la Chapelle A; Jażdżewski K
Genes Chromosomes Cancer; 2014 Jun; 53(6):516-23. PubMed ID: 24599715
[TBL] [Abstract][Full Text] [Related]
10. Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer.
Fugazzola L; Cerutti N; Mannavola D; Ghilardi G; Alberti L; Romoli R; Beck-Peccoz P
Clin Endocrinol (Oxf); 2002 Jan; 56(1):53-63. PubMed ID: 11849247
[TBL] [Abstract][Full Text] [Related]
11. HABP2 p.G534E variant in patients with family history of thyroid and breast cancer.
Pinheiro M; Drigo SA; Tonhosolo R; Andrade SCS; Marchi FA; Jurisica I; Kowalski LP; Achatz MI; Rogatto SR
Oncotarget; 2017 Jun; 8(25):40896-40905. PubMed ID: 28402931
[TBL] [Abstract][Full Text] [Related]
12. An InDel in Phospholipase-C-B-1 Is Linked with Euthyroid Multinodular Goiter.
Bakhsh AD; Ladas I; Hamshere ML; Bullock M; Kirov G; Zhang L; Taylor PN; Gregory JW; Scott-Coombes D; Völzke H; Teumer A; Mantripragada K; Williams ED; Clifton-Bligh RJ; Williams NM; Ludgate ME
Thyroid; 2018 Jul; 28(7):891-901. PubMed ID: 29897006
[TBL] [Abstract][Full Text] [Related]
13. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.
Ngan ES; Lang BH; Liu T; Shum CK; So MT; Lau DK; Leon TY; Cherny SS; Tsai SY; Lo CY; Khoo US; Tam PK; Garcia-Barceló MM
J Natl Cancer Inst; 2009 Feb; 101(3):162-75. PubMed ID: 19176457
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the c.793-1G > A splicing variant in CHEK2 gene as pathogenic: a case report.
Agiannitopoulos K; Papadopoulou E; Tsaousis GN; Pepe G; Kampouri S; Kocdor MA; Nasioulas G
BMC Med Genet; 2019 Jul; 20(1):131. PubMed ID: 31349801
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer risk is similar for CHEK2 founder and non-founder mutation carriers.
Leedom TP; LaDuca H; McFarland R; Li S; Dolinsky JS; Chao EC
Cancer Genet; 2016 Sep; 209(9):403-407. PubMed ID: 27751358
[TBL] [Abstract][Full Text] [Related]
16. Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer.
Alzahrani AS; Murugan AK; Qasem E; Alswailem MM; AlGhamdi B; Moria Y; Al-Hindi H
Endocrine; 2019 Jan; 63(1):94-100. PubMed ID: 30269267
[TBL] [Abstract][Full Text] [Related]
17. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
[TBL] [Abstract][Full Text] [Related]
18. Re-evaluating cancer risks associated with the CHEK2 p.Ser428Phe Ashkenazi Jewish founder pathogenic variant.
Laitman Y; Nielsen SM; Hatchell KE; Truty R; Bernstein-Molho R; Esplin ED; Friedman E
Fam Cancer; 2022 Jul; 21(3):305-308. PubMed ID: 34622392
[TBL] [Abstract][Full Text] [Related]
19. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
20. A novel CHEK2 variant identified by next generation sequencing in an Indian family with hereditary breast cancer syndrome.
Bhai P; Saxena R; Kulshrestha S; Verma IC
Cancer Genet; 2019 Jun; 235-236():13-17. PubMed ID: 31296309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
